If your opponent's Active Pokémon already has any damage counters on it, this attack does 60 more damage.
During your opponent's next turn, any damage done to this Pokémon by attacks is reduced by 20 (after applying Weakness and Resistance).
BREAKthrough entered circulation in 2015. Series classification for this set is XY.
Set size is 165 cards, which categorizes BREAKthrough as mid-size. As of 2026, the set is 11 years old and now falls into an established back-catalog period.
In the BREAKthrough checklist, Chesnaught occupies position #11 as a Rare Holo card.
Chesnaught appears in BREAKthrough, released in 2015. The printed flavor text states: "When it takes a defensive posture with its fists guarding its face, it could withstand a bomb blast." Core profile: Its card type is Pokémon.
The rarity label is Rare Holo. Printed HP is 160.
Energy typing is Grass. Chesnaught evolves from Quilladin.
The printed attacks highlight "Spike Lariat" and "Adamantine Press". It is weak to Fire type energy.
Chesnaught (BREAKthrough) is presently valued at about $1.47 in raw condition. The 7-day delta remains near neutral at +0.7%.
Against its 30-day baseline of $1.43, this card is pricing 2.9% higher. The 90-day window shows a floor near $1.26 and a peak around $1.47 (14% total spread), which maps to low-volatility movement.
This version is categorized as Rare Holo.
Collectors tracking Chesnaught often benchmark it against other Chesnaught cards. The current sample spans 3 comparable cards from 3 sets.
In this sample, pricing ranges between $2.25 and $5.96 (165% total span). Relative to the alternative average ($3.81), this card is -61%.
Notable alternatives include Chesnaught #XY68 (XY Black Star Promos) at $5.96, Chesnaught #14 (XY) at $2.25, and Chesnaught #5 (Kalos Starter Set) at $3.22.
Market structure summary: The latest week is near flat (+0.7%), suggesting consolidation rather than breakout behavior. Observed 90-day bounds of $1.26 and $1.47 create a 14% band, matching a low-volatility profile.
Relative to the 30-day baseline ($1.43), pricing is near equilibrium. Available graded data shows PSA 9 at $4.00, which is +172% versus raw pricing.
